Psychedelic therapy

Klarisana Expands Expertise and Vision with New Hires

Retrieved on: 
Thursday, March 11, 2021
Musicians, Singers, Health, Monica, Psychedelic therapy, Vision, Gladys, Mental health, Advertising

At Klarisana , we are proud to announce the arrival of our new Chief Behavioral Health Officer, Gladys Villa.

Key Points: 
  • At Klarisana , we are proud to announce the arrival of our new Chief Behavioral Health Officer, Gladys Villa.
  • Klarisana is also very proud to introduce Monica Sanchez, in her new role as Marketing Manager.
  • She is heavily involved in psychedelic research, education, and sharing her vision of a post-prohibitionist world.
  • Both Gladys and Monica bring to Klarisana their experience in health-positive practice procedures and messaging.

NeonMind Engages Pharma Executive Philippe Martin to Advance its Psilocybin Drug Candidates for Obesity

Retrieved on: 
Tuesday, March 9, 2021
Psychoactive drugs, Entheogens, Drug discovery, Organophosphates, Mycotoxins, Psilocybin, Psychedelic drug, Drug development, Psychedelic therapy, Psilocybin therapy

NeonMind has engaged Mr. Martin to advise on drug development programs and recommend critical resources for execution, as well as review and evaluate potential drug development paths to advance NeonMind's two psilocybin drug development programs.

Key Points: 
  • NeonMind has engaged Mr. Martin to advise on drug development programs and recommend critical resources for execution, as well as review and evaluate potential drug development paths to advance NeonMind's two psilocybin drug development programs.
  • NeonMind's first drug candidate aims to use synthetic psilocybin to enhance a patient's ability to alter behaviours that cause weight loss through psychedelic-assisted cognitive therapy.
  • The second drug candidate offers low dose synthetic psilocybin as a treatment to suppress appetite.
  • "Philippe will help us navigate the many decisions we need to make to advance synthetic psilocybin through the rigorous drug development process towards becoming an approved medical therapy."

ATMA Unveils Canada's First Psychedelic Journey Center, Offering 60 Acres of Immersive Healing and Transformation in the Foothills of the Rocky Mountains

Retrieved on: 
Friday, February 19, 2021
Atma, Psychedelic therapy, Atma, Musicians, Branches of biology, Health care

David Harder, Co-CEO of ATMA, said: "Creekside Journey Center begins the exciting rollout of our plans to create immersive retreat-style Journey Centers across Canada and beyond.

Key Points: 
  • David Harder, Co-CEO of ATMA, said: "Creekside Journey Center begins the exciting rollout of our plans to create immersive retreat-style Journey Centers across Canada and beyond.
  • Our aim is to position ATMA as the disruptor in a psychedelic renaissance that is so often focused on up-scaling the therapy."
  • "ATMA will be known for finding a place you can connect, find healing, and discover community," he said.
  • Additional patients who have recently obtained Section 56 Exemptions are also scheduled to undergo legal psychedelic therapy with ATMA next week.

Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the World's First 'MDMA in Alcohol Use Disorder' Clinical Trial

Retrieved on: 
Friday, February 19, 2021
Psychoactive drugs, Drugs, Psychotherapy, MDMA-assisted psychotherapy, MDMA, Multidisciplinary Association for Psychedelic Studies, Psychedelic therapy

Awakn to Advance Research into Phase IIb Trial

Key Points: 
  • Results published today in the Journal of Psychopharmacology, show that MDMA-Assisted Psychotherapy (3,4-methylenedioxymethamphetamine) was well tolerated by all participants.
  • Over an eight-week course of therapy, participants received two sessions with MDMA (187.5 mg each session).
  • Dr Ben Sessa, Awakn's Chief Medical Officer, commented, "This is the first clinical study into the potential effectiveness of MDMA-Assisted Psychotherapy as a treatment for Alcohol Use Disorder.
  • This was the world's first clinical research study exploring MDMA-Assisted Psychotherapy as a treatment for any addiction, and the results are promising.

Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS

Retrieved on: 
Thursday, February 18, 2021
Health sciences, Medicine, Psychiatry, Abnormal psychology, Aftermath of war, Military personnel, Post-traumatic stress disorder, Psychiatric diagnosis, Psychedelic therapy, Pharmaceutical industry

Researchers at theUniversitydiscovered this novel peptide and have completed preclinical studies supporting its efficacy.

Key Points: 
  • Researchers at theUniversitydiscovered this novel peptide and have completed preclinical studies supporting its efficacy.
  • Mr. Eric Weisblum, Chief Executive Officer of Silo Pharma, commented, Silo Pharma is committed to innovation, merging traditional therapeutics with psychedelic research, and this novel drug delivery approach.
  • Psilocybin may have the potential to bring relief to many people suffering from neurological disorders.
  • Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinsons, and other rare neurological disorders.

ATMA Launches Canada's First Psychedelic Training Program for Mental Health Professionals that Includes a Legal Psychedelic Experience

Retrieved on: 
Friday, February 12, 2021
Psychoactive drugs, Entheogens, Branches of biology, Psychiatry, Psychoactive fungi, Drug discovery, Psychedelic therapy, Psychedelic drug, Psilocybin mushroom, Psilocybin, Mental health, Legal status of psilocybin mushrooms

Starting in March 2021, ATMA and Wayfoundwill present the Psychedelic Therapy Training Program for Mental Health Professionals, which will take place through remote training as well as on-site at ATMA's Calgary Journey Center.

Key Points: 
  • Starting in March 2021, ATMA and Wayfoundwill present the Psychedelic Therapy Training Program for Mental Health Professionals, which will take place through remote training as well as on-site at ATMA's Calgary Journey Center.
  • The training allows participants to apply for an exemption from Health Canada to experience legal psychedelic-assisted therapy using psilocybin, one of the active compounds found in 'magic mushrooms'.
  • Incorporating hands-on experience with psychedelics for therapists in a legal setting is a first for the mental health community in Canada.
  • Each participant of the professional training program will also be assisted in obtaining their own exemption from Health Canada so that they may personally undergo psychedelic-assisted therapy.

COMPASS Pathways expands its Discovery Center through new collaborations with world-leading scientists

Retrieved on: 
Tuesday, February 9, 2021
Health, Disability, Mental health, Positive psychology, Social constructionism, Psychedelic therapy, Medicine, Hallucinogen

The COMPASS Discovery Center was established in August 2020 through a sponsored research agreement between COMPASS and University of the Sciences.

Key Points: 
  • The COMPASS Discovery Center was established in August 2020 through a sponsored research agreement between COMPASS and University of the Sciences.
  • Lars Wilde, Chief Business Officer and Co-founder, COMPASS Pathways, said, This is a really exciting collaboration with three of the worlds most eminent scientists in psychedelic research.
  • The Discovery Center will focus on preclinical research of novel psychedelic compounds addressing significant unmet need in a number of mental health indications.
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

Psychedelic Wellness-Focused Company Delic to Acquire Ketamine Infusion Centers LLC

Retrieved on: 
Thursday, February 4, 2021
Drugs, Psychoactive drugs, Neurochemistry, Antidepressants, Amines, Chloroarenes, Nicotinic antagonists, Sedatives, Ketamine, Psychedelia, Psychedelic therapy, KIC

VANCOUVER, BC, Feb. 4, 2021 /PRNewswire/ -Delic Holdings Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce it has entered into a binding letter agreement (the "Letter Agreement") to acquire Ketamine Infusion Centers LLC ("KIC").

Key Points: 
  • VANCOUVER, BC, Feb. 4, 2021 /PRNewswire/ -Delic Holdings Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce it has entered into a binding letter agreement (the "Letter Agreement") to acquire Ketamine Infusion Centers LLC ("KIC").
  • KIC will be Strategically Positioned to Leverage DELIC Platform and Brand: DELICexpectsto drive patients to KIC through its media platform and become a national leader
    Established History of Providing Ketamine Infusion Services.
  • By acquiring KIC, DELIC expands from being a central hub of psychedelic education, media, and information to being able to provide patients with psychedelic therapy.
  • DELIC was the first psychedelic umbrella platform and is currently a trusted source for those interested in psychedelic culture, psychedelic clinics, and more.

COMPASS Pathways announces publication in Frontiers in Psychiatry of paper on therapist training programme for psilocybin therapy

Retrieved on: 
Wednesday, February 3, 2021
Psychoactive drugs, Entheogens, Psychoactive fungi, Psilocybe, Psilocybin therapy, Psilocybin, Psychedelic drug, Psychedelic therapy, Psilocybin mushroom

The programme sets out a formal and scalable methodology for psychological support in psilocybin therapy.

Key Points: 
  • The programme sets out a formal and scalable methodology for psychological support in psilocybin therapy.
  • In psilocybin therapy, patients are given a dose of psilocybin, a psychedelic substance, in conjunction with psychological support from specially trained therapists.
  • We will continue to evolve our training programme as we progress COMP360 psilocybin therapy through clinical trials.
  • We hope that this first step encourages collaboration among therapist training providers, as we work towards bringing psilocybin therapy to all who might benefit.

20/20 Global, Inc. PsyTech the World’s Most Recognized Psychedelic Conference to Host Live Webinar on New Approaches to Ketamine-Assisted Treatment Wednesday, January 27th 2021 at 12:00 EST

Retrieved on: 
Tuesday, January 26, 2021
Drugs, Psychoactive drugs, Neurochemistry, Amines, Chloroarenes, Dissociative drugs, Nicotinic antagonists, Sedatives, Ketamine, Psychotherapy, Psychedelic therapy, Psychedelic drug

The webinar is produced by PsyTech and titled Progressive Applications of Ketamine - The Spearhead of Psychedelic Therapy.

Key Points: 
  • The webinar is produced by PsyTech and titled Progressive Applications of Ketamine - The Spearhead of Psychedelic Therapy.
  • Participants can expect a discussion on new approaches to ketamine-assisted treatment with the leading practitioners in the field.
  • Participants will hear from the expert psychiatrists, anesthesiologists, and psychotherapists at the forefront of innovative and highly impactful therapeutic ketamine treatments.
  • The virtual investor webinar is open to individual investors, institutional investors, advisors, analysts and the Psychedelic Community.